Somnomed Limited
ASX: SOM
Sharper losses narrowing as stronger device demand.
(Source: TradingView) 3-Month Performance Profile of SOM on a DTF compared to S&P/ASX 200 (XJO).
FY25 marked a turning point for SomnoMed as the company moved closer to financial stability while strengthening its global operating base. Revenue for the year reached $111.5 million, rising 22% YoY after a strong l
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
